Drug Discovery World

OCTOBER 13, 2022

There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

The Pharma Data

OCTOBER 19, 2020

Diagnostics Update : To-date the FDA has authorized 282 individual EUAs, which include 220 molecular tests, 56 antibody tests and 6 antigen tests. . DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. Diagnostics.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. The new “pathoblocker” treatment aims to disarm pathogens and suppress the disease-causing properties of P.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

FEBRUARY 15, 2023

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. Besides spheroids, another area of interest is antibody-directed cell cytotoxicity (ADCC). Reagents that can augment and enhance ADCC are of interest in addition to the antibodies themselves.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

JULY 18, 2023

Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases. Herpesviridae, Polyomaviridae, and Papillomaviridae), bacteria (e.g., Herpesviridae, Polyomaviridae, and Papillomaviridae), bacteria (e.g.,

DNA 98

DNA Genome Genomics RNA 98

The Pharma Data

OCTOBER 14, 2020

VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52